Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

BEIJING: China said on Tuesday (Oct 22) it had reached a "resolution" with India over issues related to their disputed border, after New Delhi said it had struck a deal with Beijing for military ...

The British government is being careful not to call Foreign Secretary David Lammy's trip to China a "reset" in the relationship, instead framing it as a "new starting point". It might be difficult ...

Regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China. Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 ...

For the past year, there has been one China story I haven’t been able to get out of my head: the sudden disappearance of China’s foreign minister, Qin Gang, in the summer of 2023. Qin was a ...